期刊
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 17, 期 8, 页码 2052-2061出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-08-0317
关键词
-
资金
- Cancer Research UK [C5047/A3354, C522/A8649]
- The Institute of Cancer Research
- The Everyman Campaign
- The Prostate Cancer Research Foundation
- Prostate Research Campaign UK
- The National Cancer Research Network UK
- The National Cancer Research Institute UK
- National Health and Medical Research Council, Australia [209057, 251533, 450104, 390130]
- VicHealth
- The Cancer Council Victoria
- The Cancer Council Queensland
- The Whitten Foundation
- Tattersall's
- National Human Genome Research Institute
- Health Technology Assessment Programme [96/20/06, 96/20/99]
- Department of Health, England
- Medical Research Council of England [G0500966, ID 75466]
- The National Cancer Research Institute, UK
- U.S. Department of Defense [W81XWH-04-1-0280]
- National Cancer Institute [CA56678, CA92579, CA97186]
- Fred Hutchinson Cancer Research Center
- U.S. Department of Defense, U.S Army [DAMD17-00-1-0033]
- Canadian Genetic Diseases Network
- Institut Central des Hopitaux Valaisans, Sion, Switzerland
- U.S. National Cancer Institute [R01CA72818, R01CAS4979]
- California Cancer Research [99-00524V-102-58, 99-00527V-10182]
- Academy of Finland [118413,]
- The Finnish Career Organisitions
- Sigrid Juselius Foundation
- Reino Lahtikari Foundation
- The Medical Research Fund of Tampere University Hospital
- Hannelore-Munke
- The Fred Hutchinson Cancer Research Center, Mayo
- Melbourne Collaborative Cohort Study, Montreal, Tampere, U.K
- NIH [CA089600-04]
- MRC [G0501019, G0500966] Funding Source: UKRI
- Cancer Research UK [10118] Funding Source: researchfish
- Medical Research Council [G0500966, G0501019] Funding Source: researchfish
- Academy of Finland (AKA) [118413, 118413] Funding Source: Academy of Finland (AKA)
A recent genome-wide association study found that genetic variants on chromosomes 3, 6, 7, 10, 11, 19 and X were associated with prostate cancer risk. We evaluated the most significant single-nucleotide polymorphisms (SNP) in these loci using a worldwide consortium of 13 groups (PRACTICAL). Blood DNA from 7,370 prostate cancer cases and 5,742 male controls was analyzed by genotyping assays. Odds ratios (OR) associated with each genotype were estimated using unconditional logistic regression. Six of the seven SNPs showed clear evidence of association with prostate cancer (P = 0.0007-P = 10(-17)). For each of these six SNPs, the estimated per-allele OR was similar to those previously reported and ranged from 1.12 to 1.29. One SNP on 3p12 (rs2660753) showed a weaker association than previously reported [per-allele OR, 1.08 (95% confidence interval, 1.00-1.16; P = 0.06) versus 1.18 (950% confidence interval, 1.06-1.31)]. The combined risks associated with each pair of SNPs were consistent with a multiplicative risk model. Under this model, and in combination with previously reported SNPs on 8q and 17q, these loci explain 16% of the familial risk of the disease, and men in the top 10% of the risk distribution have a 2.1-fold increased risk relative to general population rates. This study provides strong confirmation of these susceptibility loci in multiple populations and shows that they make an important contribution to prostate cancer risk prediction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据